Rui Wenbiao (5th R), director general of the Shanghai Intellectual Property Administration, visits AstraZeneca Investment (China) Co Ltd. [Photo/WeChat account: Shanghai_IPA]

Shanghai Intellectual Property Administration Director General Rui Wenbiao visited AstraZeneca Investment (China) Co Ltd on Sept 15 to learn about the intellectual property work and needs of the company.

Rui and his delegation inspected the China Health IoT Innovation Center and the China Health Innovation Hub (iCampus) established by the group and held talks with Michael Lai, general manager of AstraZeneca China.

Lai briefed Rui on the company's recent development and innovation research and thanked the Shanghai Intellectual Property Administration for its efficient handling of the company's patent disputes. He also exchanged views with Rui on the company's IP work and suggestions.

For his part, Rui said that Shanghai would continue to improve its IP protection system, as well as adhere to the principle of equal protection of the legitimate rights and interests of foreign-funded enterprises in accordance with the law.

He added that it would further focus on the needs of enterprises, respond to their concerns and constantly strengthen its strict protection, optimize service measures and build exchange platforms.

Furthermore, he said that Shanghai would strive to create a favorable environment for innovation and business for various enterprises to invest and operate in the city.